Conclusions
This economic evaluation concludes that the provision of intravenous co-amoxiclav following operative vaginal delivery is a cost-effective intervention, offering improved QOL whilst also reducing overall costs over a 6-week time period. Prior to this study, existing literature regarding the cost-effectiveness of this intervention was sparse; consequently, this study significantly adds to the literature as the first UK economic evaluation to be conducted for this intervention. Importantly, we recommend an update to current NICE guidelines, so that administration of co-amoxiclav following operative vaginal delivery is viewed as the gold-standard practice. Further research should focus on identifying and assessing the cost and benefit of alternative antibiotics against co-amoxiclav